vs
ARDELYX, INC.（ARDX）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Proto Labs Inc的季度营收约是ARDELYX, INC.的1.5倍（$139.3M vs $94.5M），Proto Labs Inc净利率更高（5.8% vs -39.8%，领先45.6%），ARDELYX, INC.同比增速更快（27.5% vs 10.4%），过去两年ARDELYX, INC.的营收复合增速更高（13.6% vs 5.3%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
ARDX vs PRLB — 直观对比
营收规模更大
PRLB
是对方的1.5倍
$94.5M
营收增速更快
ARDX
高出17.1%
10.4%
净利率更高
PRLB
高出45.6%
-39.8%
两年增速更快
ARDX
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $139.3M |
| 净利润 | $-37.6M | $8.1M |
| 毛利率 | — | 45.6% |
| 营业利润率 | — | 7.1% |
| 净利率 | -39.8% | 5.8% |
| 营收同比 | 27.5% | 10.4% |
| 净利润同比 | — | 125.4% |
| 每股收益（稀释后） | $-0.15 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXPRLB
| Q1 26 | $94.5M | $139.3M | ||
| Q4 25 | $125.2M | $136.5M | ||
| Q3 25 | $110.3M | $135.4M | ||
| Q2 25 | $97.7M | $135.1M | ||
| Q1 25 | $74.1M | $126.2M | ||
| Q4 24 | $116.1M | $121.8M | ||
| Q3 24 | $98.2M | $125.6M | ||
| Q2 24 | $73.2M | $125.6M |
净利润ARDXPRLB
| Q1 26 | $-37.6M | $8.1M | ||
| Q4 25 | $-407.0K | — | ||
| Q3 25 | $-969.0K | $7.2M | ||
| Q2 25 | $-19.1M | $4.4M | ||
| Q1 25 | $-41.1M | $3.6M | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | $-809.0K | $7.2M | ||
| Q2 24 | $-16.5M | $4.5M |
毛利率ARDXPRLB
| Q1 26 | — | 45.6% | ||
| Q4 25 | 91.3% | 44.2% | ||
| Q3 25 | 96.4% | 45.3% | ||
| Q2 25 | 87.3% | 44.3% | ||
| Q1 25 | 83.4% | 44.1% | ||
| Q4 24 | 84.3% | 42.7% | ||
| Q3 24 | 84.0% | 45.6% | ||
| Q2 24 | 87.1% | 45.0% |
营业利润率ARDXPRLB
| Q1 26 | — | 7.1% | ||
| Q4 25 | 4.1% | 5.0% | ||
| Q3 25 | 4.2% | 6.5% | ||
| Q2 25 | -14.7% | 3.7% | ||
| Q1 25 | -49.0% | 3.6% | ||
| Q4 24 | 7.0% | -1.2% | ||
| Q3 24 | 2.3% | 6.8% | ||
| Q2 24 | -18.6% | 4.8% |
净利率ARDXPRLB
| Q1 26 | -39.8% | 5.8% | ||
| Q4 25 | -0.3% | — | ||
| Q3 25 | -0.9% | 5.3% | ||
| Q2 25 | -19.5% | 3.3% | ||
| Q1 25 | -55.5% | 2.9% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | -0.8% | 5.7% | ||
| Q2 24 | -22.5% | 3.6% |
每股收益（稀释后）ARDXPRLB
| Q1 26 | $-0.15 | $0.29 | ||
| Q4 25 | $-0.01 | $0.25 | ||
| Q3 25 | $0.00 | $0.30 | ||
| Q2 25 | $-0.08 | $0.18 | ||
| Q1 25 | $-0.17 | $0.15 | ||
| Q4 24 | $0.01 | $-0.01 | ||
| Q3 24 | $0.00 | $0.29 | ||
| Q2 24 | $-0.07 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | $124.0M |
| 总债务越低越好 | $203.5M | — |
| 股东权益账面价值 | $148.6M | $683.1M |
| 总资产 | $504.5M | $778.6M |
| 负债/权益比越低杠杆越低 | 1.37× | — |
8季度趋势，按日历期对齐
现金及短期投资ARDXPRLB
| Q1 26 | $238.1M | $124.0M | ||
| Q4 25 | $68.0M | $128.1M | ||
| Q3 25 | $42.7M | $119.2M | ||
| Q2 25 | $90.0M | $103.2M | ||
| Q1 25 | $30.8M | $96.8M | ||
| Q4 24 | $64.9M | $103.1M | ||
| Q3 24 | $47.4M | $100.5M | ||
| Q2 24 | $41.9M | $112.9M |
总债务ARDXPRLB
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | — | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | — | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — |
股东权益ARDXPRLB
| Q1 26 | $148.6M | $683.1M | ||
| Q4 25 | $166.9M | $673.9M | ||
| Q3 25 | $154.3M | $664.7M | ||
| Q2 25 | $139.5M | $664.7M | ||
| Q1 25 | $145.7M | $656.8M | ||
| Q4 24 | $173.3M | $670.2M | ||
| Q3 24 | $158.3M | $680.0M | ||
| Q2 24 | $147.0M | $685.2M |
总资产ARDXPRLB
| Q1 26 | $504.5M | $778.6M | ||
| Q4 25 | $501.6M | $763.4M | ||
| Q3 25 | $486.2M | $756.9M | ||
| Q2 25 | $466.8M | $743.3M | ||
| Q1 25 | $410.2M | $737.5M | ||
| Q4 24 | $435.8M | $743.5M | ||
| Q3 24 | $367.9M | $753.8M | ||
| Q2 24 | $343.5M | $758.2M |
负债/权益比ARDXPRLB
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $17.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 2.16× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ARDXPRLB
| Q1 26 | — | $17.5M | ||
| Q4 25 | $21.0M | $16.5M | ||
| Q3 25 | $365.0K | $29.1M | ||
| Q2 25 | $-25.3M | $10.6M | ||
| Q1 25 | $-38.5M | $18.4M | ||
| Q4 24 | $9.8M | $17.3M | ||
| Q3 24 | $501.0K | $24.8M | ||
| Q2 24 | $-19.4M | $14.4M |
自由现金流ARDXPRLB
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $8.4M | ||
| Q3 25 | $209.0K | $25.0M | ||
| Q2 25 | $-26.0M | $9.1M | ||
| Q1 25 | $-38.8M | $17.1M | ||
| Q4 24 | $9.2M | $16.5M | ||
| Q3 24 | $364.0K | $23.2M | ||
| Q2 24 | $-19.5M | $10.2M |
自由现金流率ARDXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 6.2% | ||
| Q3 25 | 0.2% | 18.5% | ||
| Q2 25 | -26.6% | 6.7% | ||
| Q1 25 | -52.3% | 13.6% | ||
| Q4 24 | 7.9% | 13.5% | ||
| Q3 24 | 0.4% | 18.5% | ||
| Q2 24 | -26.7% | 8.2% |
资本支出强度ARDXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 5.9% | ||
| Q3 25 | 0.1% | 3.0% | ||
| Q2 25 | 0.7% | 1.1% | ||
| Q1 25 | 0.4% | 1.0% | ||
| Q4 24 | 0.5% | 0.7% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.2% | 3.3% |
现金转化率ARDXPRLB
| Q1 26 | — | 2.16× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 4.03× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 5.11× | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | — | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
